International Myeloma Foundation Responds to ICER Report

The International Myeloma Foundation (IMF) recently spoke out against the Institute for Clinical and Economic Review’s (ICER) report on the value of myeloma drugs. Find out what IMF had to say here. (Source: Journal of Clinical Pathways, 5/26/16)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… July 22, 2019
NPC, Analysis Group Study Focuses on Care Pathways June 27, 2019
Review of Influence: The Institute for Clinical and Economic Review February 26, 2019
Biomarkers and Companion diagnostics: Payer Insights September 26, 2019
IVI's Linthicum, Bright Discuss Mission, Value Data in Decision-Making November 28, 2018
Via Oncology's Kathy Lokay Talks Cancer Pathways in Podcast January 24, 2019
Amgen Responds to ICER's Request for Comment on Framework Update June 20, 2019